YAP1和HIF-1α表达对宫颈鳞癌患者预后的评估价值

目的分析宫颈鳞癌患者肿瘤组织中Yes相关蛋白1(YAP1)和缺氧诱导因子-1α(HIF-1α)的表达情况及其对患者预后的评估价值。方法收集85例宫颈鳞癌患者的宫颈癌组织(宫颈癌组)及85例子宫肌瘤患者的正常宫颈组织(对照组),采用免疫组织化学法检测YAP1和HIF-1α的表达情况。分析患者年龄、肿瘤直径、分化程度、TNM分期、浸润深度、淋巴结转移等临床特征与YAP1、HIF-1α表达的关系,并分析两种蛋白表达水平与患者总生存期(OS)和无进展生存期(PFS)的关系。结果宫颈癌组YAP1和HIF-1α阳性表达率分别为81.18%和84.71%,YAP1和HIF-1α高表达率分别为49.41%和54.12%,对照组中YAP1和HIF-1α几乎不表达或低表达,宫颈癌组YAP1和HIF-1α阳性表达率和高表达率均显著高于对照组(P<0.05)。宫颈鳞癌组织中YAP1表达水平与肿瘤分化程度、TNM分期、浸润深度有关(P<0.05),HIF-1α表达水平与TNM分期、浸润深度和淋巴结转移有关(P<0.05)。Log-Rank检验显示,YAP1和HIF-1α低表达的患者OS和PFS均显著长于高表达患者(P<0.05)。结论宫颈鳞癌组织中YAP1和HIF-1α高表达,与肿瘤分化程度、TNM分期、浸润深度和淋巴结转移等临床特征相关,且YAP1和HIF-1α高表达可能提示预后不良。     

口腔癌患者中 SOX9、 Beclin1 的表达与预后转归的关系

目的 探讨口腔癌患者中性别决定基因盒 9 ( sex-determining region Y box 9, SOX9)、 自噬基因 (Beclin1) 的表达与预后转归的关系。 方法 选取 2017 年 5 月至 2018 年 5 月河北省保定市第一中心医院口 腔科收治的 38 例口腔癌患者, 取其口腔癌组织标本 38 份和癌旁组织标本 30 份, 检测患者口腔癌组织中 SOX9、 Beclin1 的表达情况。 分析 SOX9、 Beclin1 阳性表达与临床病理因素的关系, 采用 COX 分析影响口腔 癌预后转归的危险因素, 分析 SOX9、 Beclin1 与预后转归的关系。 结果 口腔癌组织中 SOX9 和 Beclin1 阳 性表达率显著高于癌旁正常组织 (P< 0. 05), SOX9、 Beclin1 阳性表达与年龄、 性别无关 (P > 0. 05), 与 肿瘤分期、 分化程度和淋巴转移相关 (P< 0. 05)。 对口腔癌预后影响因素采取 Cox 逐步回归分析, 结果显 示肿瘤分期、 淋巴转移、 SOX9、 Beclin1 是影响口腔癌患者预后转归的独立危险因素 (P< 0. 05)。 SOX9 阳 性及阴性表达患者无进展生存期分别为 10 ~ 18 月 [平均 (12. 5 ± 2. 4) 月]、 14 ~ 23 月 [平均 (17. 5 ± 3. 1) 月]; Beclin1 阳性及阴性表达患者无进展生存期分别为 11 ~ 18 月 [平均 (13. 7 ± 2. 4) 月]、 13 ~ 22 月 [平均 (15. 7 ± 3. 1) 月]。 SOX9、 Beclin1 阳性表达患者无进展生存期显著低于阴性表达患者 (c²=7.969、3.315,P＜0.05）。结论 口腔癌患者中 SOX9、 Beclin1 呈阳性表达, 其表达与预后转归密切相关, 口腔癌患者 SOX9、 Beclin1 表达越高预后转归越差。     

宫颈癌组织 TMPRSS4、 LAD1 表达水平及与其患者预后的关系

目的 探讨跨膜丝氨酸蛋白酶 4 ( transmembrane protease serine 4, TMPRSS4)、 线皮素-1 ( ladinin-1, LAD1) 在宫颈癌患者组织中的表达情况及与患者预后的关系。 方法 选取 2015 年 6 月 ~ 2018 年 6 月在丹阳市人民医院手术治疗的宫颈癌患者 79 例为研究对象, 并在术中收集患者 79 例癌组织标本, 60 例 癌旁组织标本, 采用免疫组织化学染色法观察宫颈癌组织中 TMPRSS4、 LAD1 蛋白表达情况, 实时荧光定 量 PCR (qRT-PCR) 法检测组织中 TMPRSS4、 LAD1 mRNA 表达水平。 收集患者临床病理参数并对患者进 行 3 年随访, 分析 TMPRSS4、 LAD1 表达水平与患者临床病理参数的关系及影响宫颈癌患者预后的因素。 Pearson 法分析 TMPRSS4 与 LAD1 表达的相关性, 利用受试者工作特征曲线 (receiver operating characteristic curve, ROC) 分析 TMPRSS4、 LAD1 水平对患者预后的预测价值。 结果 宫颈癌患者癌组织 TMPRSS4、 LAD1 表达水平均高于癌旁组织 (P< 0. 05)。 宫颈癌组织中 TMPRSS4 和 LAD1 的表达水平呈明显正相关 (r = 0. 249, P< 0. 05)。 宫颈癌组织中 TMPRSS4 与 LAD1 蛋白表达与患者 FIGO 分期和肿瘤分化程度有关 (P< 0. 05), FIGO 分期、 肿瘤分化程度、 TMPRSS4、 LAD1 蛋白表达水平是影响患者预后的因素 (P< 0. 05)。 预后存活患者癌组织中 TMPRSS4 和 LAD1 水平均显著低于预后死亡患者 (P< 0. 05)。 ROC 结果显示, TMPRSS4 和 LAD1 水平评估患者预后的曲线下面积分别为 0. 756、 0. 909, 对应的敏感度分别为 91. 11 % 、 52. 94 % , 特异度分别为 85. 29 % 、 85. 29 % ; 二者联合评估患者预后的曲线下面积为 0. 952, 敏感度为 88. 89 % , 特异度为 88. 24 % 。 结论 TMPRSS4、 LAD1 在宫颈癌患者组织中均高表达, 二者表达呈明显正 相关, 可应用于评估患者预后。     

Six1和Six4在食管鳞状细胞癌组织中的表达及其与预后的关系北大核心CSCD

目的探讨Six1和Six4在食管鳞状细胞癌（简称鳞癌）组织中的表达及其与临床病理特征及预后的关系。方法应用组织芯片技术、免疫组织化学EnVision法检测Six1和Six4在292例食管鳞癌组织及其相应的癌旁正常食管上皮组织中的表达水平,分析两者表达与临床病理特征及预后之间的关系。结果在292例食管鳞癌患者中,Six1、Six4蛋白在癌组织的阳性率分别为72．9％（213／292）和56．2％（164／292）,明显高于癌旁正常组织的阳性率,分别为33．2％（97／292）和32．5％（95／292）,差异具有统计学意义（P〈0．05）。X2检验结果显示Six1蛋白表达与肿瘤大小、肿瘤浸润深度及生存状态相关,其在死亡组患者的阳性率82．3％（130／158）,明显高于生存组阳性率61．9％（83／134,P〈0．05）。Six4蛋白表达与肿瘤分化程度及肿瘤浸润深度相关,肿瘤分化程度越高、浸润深度越深其阳性率越高。单因素Log-rank分析显示性别、TNM分期、Six1蛋白表达与食管鳞癌患者的总生存率相关（P〈0．05）。Six1蛋白表达阴性组5年生存率51．9％（41／79）高于阳性组的43．7％（93／213）,差异具有统计学意义（X^2=4．079,P=0．043）,其他临床参数与预后均未显示统计学意义（P〉0．05）。多因素Cox比例风险模型分析显示,TNM分期、Six1蛋白表达水平是影响食管癌术后患者预后的独立因素（P〈0．05）。结论Six1和Six4蛋白在食管鳞癌组织中均高表达,其表达水平与食管鳞癌发生发展及预后密切相关,Six1蛋白高表达是食管鳞癌患者预后不良的因素,可作为临床预测食管鳞癌患者预后的一个重要指标。     

肺腺癌转移相关转录因子1在口腔鳞状细胞癌组织中的表达及临床意义

目的分析口腔鳞状细胞癌组织中长链非编码RNA(lncRNA)肺腺癌转移相关转录因子1(MALAT1)的表达及其临床意义。方法收集口腔鳞癌组织标本81例和正常口腔黏膜组织20例,分别设为口腔鳞癌组和健康对照组。采用RT-PCR方法检测2组组织中lncRNA MALAT1表达情况,统计分析lncRNA MALAT1表达与病理资料特征的关系,Kaplan-Meier分析lncRNA MALAT1表达和生存预后间的关系。结果与健康对照组相比,lncRNA MALAT1在口腔鳞癌组中表达明显增高,差异有统计学意义(P 0. 05);口腔癌组织中lncRNA MALAT1的相对表达量在不同肿瘤分期、肿瘤分化程度和有无颈部淋巴结转移间比较,差异均有统计学意义(P 0. 05);而在不同年龄、性别、肿瘤大小及肿瘤类型间比较,差异均无统计学意义(P 0. 05); lncRNA MALAT1高表达组和低表达组患者的3年总体生存率(OS)分别为45. 9%(17/37)、65. 9%(29/44),Kaplan-Meier生存分析(log-rank检验)表明MALAT1高表达组患者3年OS显著低于MALAT1低表达组患者,差异有统计学意义(P 0. 05)。结论口腔鳞癌组织中lncRNA MALAT1表达增高,其表达水平与口腔鳞癌患者的不良预后有关,在口腔鳞癌组织中检测其表达可能有助于肿瘤的诊断及作为药物治疗的靶点。     

胰岛素样生长因子2 mRNA结合蛋白3在肺鳞癌的表达及预后分析

目的 探讨胰岛素样生长因子2 mRNA结合蛋白3(IMP3)在肺鳞癌中的表达及评价预后的意义.方法 应用免疫组化染色,检测92例肺鳞癌及癌旁组织中IMP3蛋白的表达,结合临床病理学指标及总生存期进行统计学分析.结果 肺鳞癌组织中IMP3阳性表达率明显高于癌旁正常组织(x2=70.145,P＜0.01),IMP3蛋白在肺鳞癌中的表达与组织分化程度低、有转移以及病理分期高密切相关(x2分别为9.811、11.926和7.136,P＜0.01);癌组织中IMP3蛋白的表达与患者术后总生存期呈负相关(Log-rank=23.889,P＜0.01),IMP3阳性表达是预后的独立风险因素(风险比:0.436,95％置信区间:0.247 ～0.768,P＜0.01).结论 IMP3表达的肺鳞癌预后较差,可作为新的肺鳞癌标记物.     

受体相互作用蛋白1RIP1在食管鳞癌的表达及意义

目的明确受体相互作用蛋白1 RIP1在人食管鳞癌组织中的表达及与临床病理因素、病人预后的关系。方法使用免疫组化SP法检测76例人食管鳞癌组织和相对应的癌旁正常食管黏膜中RIP1的表达状况,并分析与临床病理因素如病人的性别、年龄、肿瘤大小、浸润深度、临床分期、分级、有无淋巴结转移的关系,并进行了随访。结果76例食管鳞癌中RIP1阳性的病例有53例,占69.7%,癌旁组织RIP1阳性的只有19例,占25%,差异有统计学意义,RIP1的阳性表达与病人的性别、年龄、肿瘤大小无关,与浸润深度、临床分期、分级、有无淋巴结转移成正相关,随访结果表明:食管鳞癌中RIP1阳性率越高,病人生存期越短,预后越差,RIP1蛋白的表达是个预后不良的独立因素。结论 RIP1在食管鳞癌中表达增高,可能参与食管鳞癌的发生。     

长链非编码RNA WIF1-1在食管鳞状细胞癌组织中的表达及其临床意义

目的:探究食管鳞状细胞癌组织及癌旁组织中长链非编码RNA(long noncoding RNA,lncRNA)WIF1-1的表达水平,并评估其对患者预后的价值.方法:使用实时荧光定量PCR检测50例食管鳞状细胞癌组织样本及其对应同源的癌旁组织样本中lncRNA WIF1-1的表达水平,分析临床病理特征及其与患者预后的相关性.结果:食管鳞状细胞癌组织中lncRNA WIF1-1的表达水平明显低于癌旁组织,差异有统计学意义(P<0.001).进一步分析发现:lncRNA WIF1-1的表达水平与食管鳞状细胞癌的淋巴结转移、TNM分期和临床分期之间呈负相关.对预后资料分析发现:lncRNA WIF1-1表达水平较低的食管鳞癌患者的总生存时间(overall survival,OS)以及无进展生存期(progression-free survival,PFS)均较短.单因素及多因素分析结果显示:lncRNA WIF1-1可作为食管鳞状细胞癌患者OS和PFS的独立危险因素.结论:lncRNA WIF1-1可能在食管鳞状细胞癌中发挥抑癌基因的作用,其表达量与患者预后具有相关性,有可能成为食管鳞状细胞癌的治疗靶点.     

可诱导 T 细胞共刺激分子在结肠癌组织中的表达情况及其与 远期生存的相关性研究

目的 探讨分析可诱导 T 细胞共刺激分子 (inducible T-cell co-stimulator, ICOS) 在结肠癌组织中 的表达情况及其与远期生存的相关性。 方法 选取 2018 年 5 月至 2019 年 5 月期间在大连大学附属新华医 院进行手术切除结肠组织的 206 例结肠癌患者作为研究对象, 取其结肠癌组织及癌旁组织标本, 使用荧光 定量 PCR 检测结肠癌组织及癌旁组织中可诱导 T 细胞共刺激分子表达水平, 分析其表达与临床病理特征的 关系及远期生存的相关性。 结果 结肠癌组织中 ICOS 表达水平 (8. 73 ± 2. 25) 显著低于癌旁组织的 (18. 54 ± 3. 26), 差异有统计学意义 (P< 0. 05); 结肠癌组织中 ICOS 表达水平与肿瘤直径、 远处转移、 临 床分期、 淋巴结转移有关 ( P < 0. 05), 与年龄、 性别、 肿瘤部位、 分化程度差异无统计学意义 ( P > 0. 05); ICOS 表达在 206 例结肠癌组织的中低表达 117 例, 高表达 89 例; ICOS 高表达和低表达与临床病理 因素进行 Logistic 二次回归分析结果显示, ICOS 表达与肿瘤大小、 临床分期、 淋巴结转移、 远处转移有关 (P< 0. 05), 与年龄、 性别、 肿瘤位置、 分化程度无关 (P > 0. 05); 随访截止至 2021 年 9 月 30 日, 206 例 结肠癌患者存活率 83. 01 % (171 / 206), 死亡率 16. 99 % (35 / 206), 中位生存时间为 (23. 5 ± 3. 3) 个 月。 ICOS 高表达的 89 例结肠癌患者的中位生存期为 (27. 4 ± 3. 2) 个月, 95 % CI 为 2. 234 ~ 6. 147; ICOS 低表达的 117 例结肠癌患者的中位生存期为 (16. 3 ± 4. 3) 个月, 95 % CI 为 1. 458 ~ 5. 237, ICOS 高表达结 肠癌患者中位生存期显著高于 ICOS 低表达者 (P< 0. 05)。 结论 ICOS 在结肠癌组织中呈较低表达, 其表 达水平与患者远期生存呈正相关关系, 其水平可作为结肠癌患者预后生存的重要评估指标。     

组织蛋白酶D新的糖基化异构体在肺癌中表达的临床意义及其与预后的相关性

目的 探讨组织蛋白酶D（CTSD）新的糖基化异构体与肺癌临床病理特征及预后的相关性。 方法 应用免疫组织化学和半定量RT PCR方法检测119例肺癌组织和39例癌旁组织中CTSD的表达;Western blotting分析CTSD各异构体表达特点;去糖基化实验检测CTSD 蛋白的糖基化修饰;Kaplan-Meier分析66kD异构体、临床病理资料与肺癌术后整体生存期的相关性。 结果 CTSD在肺鳞癌、腺癌和小细胞肺癌组织中高表达;66kD蛋白为CTSD新的糖基化异构体,该异构体表达与肺癌组织类型、临床分期、淋巴结转移和患者的吸烟史密切相关（P<0.05）,阳性表达和阴性表达患者术后中位生存时间分别为20.0和30.0个月（P<0.05）;肺癌组织类型、临床分期、淋巴结转移、肿瘤大小和66kD异构体表达是影响肺癌预后的独立因素。 结论 CTSD 66kD异构体阳性表达可能是肺癌预后不良的分子标志物之一。     

pEZR~(Thr567)在肺鳞癌中的表达及临床病理学意义

目的:探讨第567位苏氨酸磷酸化的埃兹蛋白(p EZRThr567)在肺鳞癌、癌旁及正常肺组织中的表达及其临床病理学意义。方法:用免疫组化法检测p EZRThr567在肺癌、癌旁及正常肺组织中的表达,并分析其异常表达与临床病理学特点之间的相关性;用免疫荧光染色法检测p EZRThr567在肺鳞癌细胞EBC-1中的定位情况。结果:p EZRThr567蛋白在肺鳞癌组织中的表达明显高于癌旁组织和正常肺组织(P0.01);p EZRThr567蛋白主要表达于细胞膜,且其表达与肿瘤分化程度、临床分期和有无淋巴结转移密切相关(P0.05)。结论:p EZRThr567蛋白可作为肺鳞癌恶性进展的有效分子指标。     

RKIP在不同类型肺癌中表达的变化及临床意义

目的 观察Raf激酶抑制蛋白（RKIP）在不同类型肺癌中表达的变化及探讨其临床价值。方法 选取鳞癌21例、腺癌23例及小细胞肺癌10例设为实验组,肺良性病变10例设为对照组,采用免疫组化的方法检测RKIP的表达,观察在不同类型肺癌中表达的差异及与临床分期的关系。结果 与对照组比较,实验组中RKIP的表达水平均降低,差异有统计学意义（P＜0.05）。实验组中RKIP的表达最低的是小细胞癌,其次为鳞癌,再次腺癌。对腺癌进一步研究发现,与Ⅰ及Ⅱ期比较,RKIP在Ⅲ及Ⅳ期的表达更低;与Ⅰ期比较,RKIP在Ⅱ期中表达稍有减低,但差异无统计学意义（P＞0.05）;与Ⅲ期比较,RKIP在Ⅳ期中表达稍有减低,但差异无统计学意义（P＞0.05）。磷酸化ERK1/2（p-ERK1/2）的表达趋势与RKIP相反,与Ⅰ和Ⅱ期比较,在Ⅲ和Ⅳ期中表达明显升高。相关性分析显示,RKIP与p-ERK1/2的表达呈负相关（r=-0.893,P＜0.05）。结论 RKIP表达水平的缺失可能促进了ERK1/2的磷酸化,从而促进了肺癌的发生及发展,因此检测RKIP的表达水平可能对诊断肺癌及分期预后有重要的临床价值。     

Peroxiredoxin 4 as an independent prognostic marker for survival in patients with early-stage lung squamous cell carcinoma

Objectives: Peroxiredoxin 4 (Prx 4) is a newly emerging antioxidant protein that has been studied in several human cancers. Recently, it was revealed that Prx 4 is highly expressed in human lung cancer and is needed for the promotion of lung cancer progression in vitro. However, there are no clinical data regarding the association of Prx 4 and prognosis in lung cancer. Materials and methods: The Prx 4 expression state as a prognostic indicator was assessed by immunohistochemical staining in 142 patients with stage II non-small cell lung cancer (NSCLC) who had undergone curative surgery between 2006 and 2010. The association between the degree of Prx 4 expression and several clinicopathologic parameters was then evaluated by statistical analyses. Results: The degree of Prx 4 expression was associated with histology and recurrence in the overall NSCLC patient group, with the proportion of patients with positive Prx 4 expression significantly higher for the adenocarcinoma subtype (39/70, 56%) than the squamous cell carcinoma subtype (23/72, 32%) (P = 0.004). However, when subgroup analyses according to histopathology were performed in terms of recurrence, positive Prx 4 expression was significantly correlated with higher recurrence rates (P = 0.003) and shorter disease-free survival (DFS) (P = 0.003, hazard ratio = 3.910) in patients with squamous cell carcinoma. In contrast, no meaningful relationship was observed between the level of Prx 4 expression and DFS in the adenocarcinoma subgroup. Conclusion: Positive Prx 4 expression is significantly correlated with recurrence and shorter DFS in patients with early-stage lung squamous cell carcinoma.     

Loss of DLC1 is an independent prognostic factor in patients with oral squamous cell carcinoma

Deleted in liver cancer (DLC1), a Rho GTPase-activating protein, was observed to be differentially expressed in oral squamous cell carcinoma in comparison with normal tissues using tissue proteomics. In the current study, we investigated the clinical significance of loss of DLC1 expression in different stages of development of oral squamous cell carcinoma to determine its potential as a biomarker for oral dysplasia and prognosis of oral squamous cell carcinoma. Immunohistochemical analysis of DLC1 expression was carried out in oral squamous cell carcinoma patients (n=214), dysplasia (n=51), hyperplastic squamous mucosa (n=45), and histologically normal oral tissues (n=80), and correlated with clinicopathological parameters and disease prognosis over 91 months for oral squamous cell carcinomas. Loss of DLC1 expression was observed in oral squamous cell carcinoma (64%), oral dysplasia (31%), hyperplastic squamous mucosa (22%), and normal mucosa (16%). Significant loss of DLC1 expression was observed in oral squamous cell carcinomas as compared with dysplasia (P<0.001, odds ratio=3.8, 95% CI=2.0-7.3), suggesting it may be an important event involved in cancer progression. Among oral squamous cell carcinomas, the loss of DLC1 expression was significantly associated with poor prognosis (P=0.021, hazards ratio (HR)=1.8, 95% CI=1.1-2.9). Multivariate analysis revealed loss of DLC1 (P=0.023, HR=2.1, 95% CI=1.2-3.9) and histopathological grade (P=0.015, HR=1.7, 95% CI=1.1-2.7) to be independent predictors for disease-free survival in oral squamous cell carcinoma patients in comparison with known prognostic factors, viz. tumor stage, nodal status, and overall stage. Loss of DLC1 expression emerged as an important biomarker for predicting patients diagnosed with oral dysplasia at high risk of transformation upon future validation in longitudinal studies. Loss of DLC1 expression is a poor prognostic marker for oral squamous cell carcinoma patients.     

Gain of 1q25-32, 12q23-24.3, and 17q12-22 facilitates tumorigenesis and progression of human squamous cell lung cancer

To explore the genetic changes involved in the stepwise development of lung cancer, we have determined the genetic events associated with the histological progression from normal bronchial epithelium to squamous cell carcinoma. Comparative genomic hybridization was used to identify chromosomal imbalances in 54 microdissected samples, including squamous metaplasia, dysplasia, carcinoma in situ, and invasive tumour derived from 23 patients with squamous cell carcinoma of the lung. Histopathological progression was accompanied by an increased number of chromosomal abnormalities. Gains of 1q25-32, 12q23-24.3, and 17q12-22, in particular, were detected at high frequencies in both carcinoma in situ and invasive tumours and were found more often in the cases with lymph node metastases than in those without. Our previous expression profiling of squamous cell carcinomas had identified overexpression of laminin5 gamma2, a gene located at 1q25-31. Therefore, this was investigated at the protein level by immunohistochemical analysis in 336 samples of squamous cell carcinoma of the lung. Consistent with the genomic data for this region, the expression level of laminin5 gamma2 was higher in the primary tumours with lymph node metastases than in tumours without metastases (p = 0.012). These data suggest that gains of genes from 1q25-32, 12q23-24.3, and 17q12-22 facilitate tumorigenesis and progression of squamous cell carcinoma of the lung, and may serve as potential predictors for this disease.     

Expression of integrin-linked kinase in lung squamous cell carcinoma and adenocarcinoma: correlation with E-cadherin expression,tumor microvessel density and clinical outcome

Integrin-linked kinase (ILK) plays a role in integrin signaling-mediated cell-extracellular matrix interactions and is involved in signal transduction pathways to control cell survival, differentiation, and proliferation in mammalian cells. ILK has been implicated in the progression of several human malignancies. However, its function in malignant tumors is not fully enunciated. Previous in vitro studies also implicated ILK in the regulation of E-cadherin expression and vascular endothelial growth factor expression. In the current study, we investigated the protein expression of ILK and its correlation with clinicopathological profiles, E-cadherin expression, microvessel density (MVD) and clinical outcome in 57 lung squamous cell carcinoma and 44 adenocarcinoma, using immunohistochemistry. No ILK was detected in normal bronchial epithelium, while it was positively expressed in 39 (68.42%) squamous cell carcinoma cases and 27 (61.36%) adenocarcinoma cases. Positive ILK expression was significantly associated with advanced TNM stage (P = 0.022) in adenocarcinoma, and associated with high MVD in lung squamous cell carcinoma (P < 0.001) and adenocarcinoma (P = 0.049). The Spearman's correlation test revealed that increased ILK expression was correlated with reduced E-cadherin expression in lung squamous cell carcinoma (correlation coefficient = 0.364, P = 0.005). Moreover, the Kaplan–Meier survival analysis showed that ILK, E-cadherin, and MVD were all statistically significant prognostic factors in patients with lung squamous cell carcinoma and adenocarcinoma. Measuring ILK and E-cadherin expression, and MVD may contribute to a better understanding of the prognosis of patients with lung squamous cell carcinoma and adenocarcinoma.     

窖蛋白-1在肺癌中的表达及意义

目的 探讨窖蛋白-1（caveolin-1）在不同类型肺癌组织中的表达及其与微血管密度（MVD）和临床病理因素之间的关系。方法 对154例原发性肺癌、相应癌旁正常肺组织及36例淋巴结转移癌行caveolin-1免疫组织化学染色;对154例原发性肺癌行CD34免疫组织化学（SP法）染色并进行微血管密度计数;Western印迹法检测其中50例新鲜肺癌组织及其癌旁正常肺组织中caveolin-1的表达情况。结果 caveolin-1为膜／质表达蛋白,在正常支气管上皮细胞和肺泡上皮细胞中的阳性率为100％。在肺癌组织中的阳性率为59．1％（91／154）,低于癌旁正常肺组织,P＜0．01;Western印迹结果进一步证实caveolin-1在肺鳞癌、肺腺癌组织中的表达均显著低于癌旁正常肺组织,P＜0．01。caveolin-1在小细胞肺癌（SCLC）和非小细胞肺癌（NSCLC）中的阳性率分别为7．1％和64．3％,二者间差异有统计学意义,P＜0．01。NSCLC中,有淋巴结转移组caveolin-1表达高于无淋巴结转移组（P=0．005）;Ⅲ、Ⅳ期组caveolin-1表达显著高于Ⅰ、Ⅱ期组（P=0．042）,caveolin-1表达与NSCLC的其他临床病理因素及MVD值无关（P＞0．05）。结论caveolin-1其作为一种肿瘤抑制因子的同时,可能还具有促进NSCLC进展和转移的活性。     

Up-regulation of long non-coding RNA CCAT2 correlates with tumor metastasis and poor prognosis in cervical squamous cell cancer patients

Background: Dysregulation of long non-coding RNAs (lncRNAs) plays critical roles in tumor progression. The purpose of this study was to investigate the relationship between lncRNA CCAT2 expression and cervical squamous cell cancer susceptibility and prognosis. Methods: Expression levels of lncRNA CCAT2 in 123 cervical squamous cell tumor specimens were determined by quantitative real-time PCR (qRT-PCR), to clarify the clinical significance of lncRNA CCAT2 in cervical squamous cell cancer, we further discussed the relationship between lncRNA CCAT2 expression and overall survival (OS) and progression-free survival (PFS). Results: In the present study, we found that lncRNA CCAT2 was up-regulated in cervical squamous cell cancer tissues compared to the adjacent non-tumor tissues. In addition, the high lncRNA CCAT2 expression was significantly associated with the FIGO stage, lymph node metastasis and depth of cervical invasion (P<0.05). Furthermore, patients with high expression of lncRNA CCAT2 had poor OS (HR=2.813, 95% CI: 1.504-6.172; P=0.017), and PFS rates (HR=3.072, 95% CI: 1.716-8.174; P=0.008). Multivariate Cox proportional hazard model analysis demonstrated that high lncRNA CCAT2 expression was an independent poor prognostic factor for cervical squamous cell cancer patients. Conclusions: Our study suggested that high expression of lncRNA CCAT2 is related to the prognosis of cervical squamous cell cancer; it may be a new prognostic biomarker and potential therapeutic target for cervical squamous cell cancer intervention.